TY - JOUR
T1 - Prognostic Factors and Staging in Multiple Myeloma
AU - Fonseca, Rafael
AU - San Miguel, Jesus
PY - 2007/12
Y1 - 2007/12
N2 - The field of multiple myeloma prognostication is replete with studies that have shown the value of independent predictors in determining clinical outcome. It is clear that host factors and factors intrinsic to the cells are the ultimate determinants of prognosis. In the immediate period after diagnosis, those factors related to the host are likely to be more relevant, whereas with passing time factors intrinsic to the cells predominate. At a minimum, we recommend that a comprehensive molecular cytogenetic assessment be performed at diagnosis, together with conventional evaluation, including β2-microglobulin and albumin. In addition, information on proliferative activity of plasma cells may be of value. The introduction of novel methods of prognostication should be strongly considered in all clinical trials.
AB - The field of multiple myeloma prognostication is replete with studies that have shown the value of independent predictors in determining clinical outcome. It is clear that host factors and factors intrinsic to the cells are the ultimate determinants of prognosis. In the immediate period after diagnosis, those factors related to the host are likely to be more relevant, whereas with passing time factors intrinsic to the cells predominate. At a minimum, we recommend that a comprehensive molecular cytogenetic assessment be performed at diagnosis, together with conventional evaluation, including β2-microglobulin and albumin. In addition, information on proliferative activity of plasma cells may be of value. The introduction of novel methods of prognostication should be strongly considered in all clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=35948990849&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35948990849&partnerID=8YFLogxK
U2 - 10.1016/j.hoc.2007.08.010
DO - 10.1016/j.hoc.2007.08.010
M3 - Review article
C2 - 17996591
AN - SCOPUS:35948990849
SN - 0889-8588
VL - 21
SP - 1115
EP - 1140
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 6
ER -